- Agreement grants Astellas rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targets - Sangamo to receive a $20 million upfront license fee ...
Gene therapy (introducing genetic material into living cells to fix, replace, enhance, or block a faulty gene) is rapidly gaining traction as a strategy for the treatment of genetic diseases. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback